enGene Holdings

ENGN

Market cap $590M

8.81 USD

+0.31

3.65%

At close Updated Jan 9, 4:00 PM EST

Pre-market

After hours

9.00

+0.19

2.16%

1 day

3.65%

5 days

-1.01%

1 month

7.05%

3 months

-0.9%

6 months

130.03%

Year to date

-0.45%

1 year

15.77%

5 years

-55.95%

10 years

-55.95%

About: enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Employees: 82

Healthcare Biotechnology